McCarron Robyn H, Rathee Ruchika, Yang Sharon, Thavachelvi Chandran
Cambridgeshire and Peterborough NHS Foundation Trust, UK.
Department of Psychiatry, University of Cambridge, Cambridge, UK.
Clin Neuropsychiatry. 2020 Oct;17(5):295-299. doi: 10.36131/cnfioritieditore20200506.
The COVID-19 pandemic has created an unprecedented situation demanding a rapid response to a barrage of unknown risks. Issues around infection control, resource allocation and treatment delivery have threatened the viability and accessibility of Electroconvulsive Therapy (ECT) services. Additionally, there are unquantified risks around the delivery and effect of ECT in patients who have had COVID-19. We discuss two cases where ECT was restarted in older-adults who had had symptomatic COVID-19. We consider the importance of clinical assessment, multi-speciality team involvement, and comprehensive risk assessment in making high stakes treatment decisions around ECT in patients with COVID-19. Although more research and international multi-speciality collaboration is required to develop evidence-based guidance, it is vital that we maintain equitable access to safe, effective and potentially life-saving ECT during this pandemic.
新冠疫情造成了前所未有的局面,需要对一系列未知风险迅速做出应对。感染控制、资源分配和治疗提供等问题威胁到了电休克治疗(ECT)服务的可行性和可及性。此外,对于感染过新冠的患者,ECT的实施和效果存在无法量化的风险。我们讨论了两例在出现症状性新冠感染的老年人中重启ECT的病例。我们认为,在针对新冠患者做出有关ECT的重大治疗决策时,临床评估、多专科团队参与和全面风险评估非常重要。尽管需要更多研究和国际多专科合作来制定循证指南,但在这场疫情期间,维持对安全、有效且可能挽救生命的ECT的公平可及性至关重要。